Cumberland Pharmaceuticals Insider Adds Shares via 10b5-1 Plan

Rhea-AI Filing Summary

SEC Form 4 filing dated 07/11/2025 reports a series of open-market purchases of Cumberland Pharmaceuticals Inc. (CPIX) common stock by director Caroline Young.

Transaction details:

• 20 separate buy transactions executed from 06/02/2025 to 06/30/2025.
• Total shares acquired: 84 (nineteen lots of 4 shares and one lot of 8 shares).
• Price range: $2.60 – $6.00 per share.
• Weighted-average purchase price: approximately $4.81 per share (derived from disclosed price and share data).
• Total cost: about $403.60.

All trades were automatically executed under a Rule 10b5-1 trading plan adopted on 11/14/2024, as noted in the Explanation of Responses.

Following the reported transactions Ms. Young’s direct beneficial ownership stands at 32,653 CPIX shares. No derivative security activity was reported, and the filing indicates that Ms. Young continues to serve as a director of the company.

The filing does not provide information on company operations, earnings or additional insider activity. The share-price pattern shows a steady decline over the month—from $5.20 on 06/02 to $2.74 on 06/30—suggesting the purchases occurred during a period of price weakness.

Positive

• Director increased direct holdings by 84 shares, bringing total ownership to 32,653 shares.
• All transactions executed under a pre-arranged Rule 10b5-1 plan, demonstrating compliance with insider-trading regulations.

Negative

• Purchase size is immaterial relative to typical trading volumes and likely has no meaningful impact on insider ownership percentage.
• Disclosed share prices fell from $5.20 to $2.74 during the transaction window, reflecting significant share-price weakness.

Insights

Financial Analyst

TL;DR: Small automatic insider buys (84 shares) under 10b5-1 plan; positive signal limited by immaterial size and falling prices.

The Form 4 indicates consistent daily buying by director Caroline Young but at very low volume—84 shares over a month is negligible versus typical public float, limiting any valuation impact. The purchases were pre-scheduled, reducing informational content compared with discretionary buying. However, the director’s ownership increased and now totals 32,653 shares, which may marginally align interests with shareholders. Notably, traded prices dropped more than 50% during the period ($5.94 to $2.60), implying the company’s stock was under pressure while the plan was executed. From a portfolio perspective the filing is informational, not actionable; it neither alters earnings outlook nor capital structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Caroline

(Last) (First) (Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2025		P	V	4(1)	A	$5.2	32,573	D
Common Stock	06/03/2025		P	V	4(1)	A	$5.61	32,577	D
Common Stock	06/04/2025		P	V	4(1)	A	$5.75	32,581	D
Common Stock	06/05/2025		P	V	4(1)	A	$5.46	32,585	D
Common Stock	06/06/2025		P	V	4(1)	A	$5.57	32,589	D
Common Stock	06/09/2025		P	V	4(1)	A	$5.94	32,593	D
Common Stock	06/10/2025		P	V	4(1)	A	$6	32,597	D
Common Stock	06/11/2025		P	V	4(1)	A	$5.57	32,601	D
Common Stock	06/12/2025		P	V	4(1)	A	$5.67	32,605	D
Common Stock	06/13/2025		P	V	4(1)	A	$5.81	32,609	D
Common Stock	06/16/2025		P	V	4(1)	A	$5.32	32,613	D
Common Stock	06/17/2025		P	V	4(1)	A	$5.61	32,617	D
Common Stock	06/18/2025		P	V	4(1)	A	$5.52	32,621	D
Common Stock	06/20/2025		P	V	4(1)	A	$5.29	32,625	D
Common Stock	06/23/2025		P	V	4(1)	A	$4.61	32,629	D
Common Stock	06/24/2025		P	V	4(1)	A	$3.91	32,633	D
Common Stock	06/25/2025		P	V	4(1)	A	$3.27	32,637	D
Common Stock	06/26/2025		P	V	4(1)	A	$2.71	32,641	D
Common Stock	06/27/2025		P	V	4(1)	A	$2.6	32,645	D
Common Stock	06/30/2025		P	V	8(1)	A	$2.74	32,653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	Caroline Young by /s/ John Hamm as attorney-in-fact	07/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CPIX shares did Caroline Young purchase according to the Form 4?

She bought 84 shares between 06/02/2025 and 06/30/2025.

What was the price range of Caroline Young’s CPIX purchases?

Prices ranged from $2.60 to $6.00 per share.

What is Caroline Young’s total ownership in Cumberland Pharmaceuticals after the transactions?

She now directly owns 32,653 CPIX shares.

Were the transactions conducted under a 10b5-1 trading plan?

Yes. The filing states they were executed under a Rule 10b5-1 plan adopted on 11/14/2024.

What role does Caroline Young hold at Cumberland Pharmaceuticals?

She is listed as a Director of the company.